{"id":"fluphenazine-enanthate","rwe":[],"tags":[{"label":"Phenothiazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(3) dopamine receptor","category":"target"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"ADRA1A","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Psychotic disorder","category":"indication"},{"label":"Schizophrenia","category":"indication"},{"label":"Apothecon","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Acute disease of cardiovascular system","Alcoholism","Anemia","Angina pectoris","At risk for aspiration","Benign prostatic hyperplasia","Bradycardia","Breastfeeding (mother)","Carcinoma of female breast","Chronic disease of respiratory system","Chronic heart failure","Coma","Conduction disorder of the heart","Congenital long QT syndrome","Disease of liver","Epilepsy","Extrapyramidal disease","Glaucoma","Hyperglycemia","Hyperprolactinemia","Leukopenia","Metabolic syndrome X","Myocardial infarction","Myocardial ischemia","Neuroleptic malignant syndrome"]},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3287/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$120","description":"FLUPHENAZINE 1 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUPHENAZINE ENANTHATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:51:55.729506+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:52:01.112106+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUPHENAZINE ENANTHATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:52:02.175839+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dopamine D2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:52:03.244842+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200951/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:52:02.898498+00:00"}},"allNames":"moditen enanthate","offLabel":[],"synonyms":["fluphenazine enanthate","moditen enanthate","prolixin enanthate"],"timeline":[{"date":"1967-03-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Apothecon)"}],"aiSummary":"Moditen Enanthate, also known as Fluphenazine Enanthate, is a phenothiazine antipsychotic medication originally developed by Apothecor and currently owned by the same company. It targets the D3 dopamine receptor to treat psychotic disorders and schizophrenia. This medication is classified as a small molecule and was FDA-approved in 1967. As it is off-patent, there are no active generic manufacturers. Key safety considerations include the potential for extrapyramidal symptoms and tardive dyskinesia.","approvals":[{"date":"1967-03-15","orphan":false,"company":"APOTHECON","regulator":"FDA"}],"brandName":"Moditen Enanthate","ecosystem":[{"indication":"Psychotic disorder","otherDrugs":[{"name":"acetophenazine","slug":"acetophenazine","company":"Schering"},{"name":"chlorpromazine","slug":"chlorpromazine","company":"Glaxosmithkline"},{"name":"fluphenazine","slug":"fluphenazine","company":""},{"name":"fluphenazine decanoate","slug":"fluphenazine-decanoate","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"D(3) dopamine receptor","novelty":"Follow-on","targets":[{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"DRD5","source":"DrugCentral","target":"D(1B) dopamine receptor","protein":"D(1B) dopamine receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"DRD1","source":"DrugCentral","target":"D(1A) dopamine receptor","protein":"D(1A) dopamine receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","drugClass":"Phenothiazine","explanation":"","oneSentence":"","technicalDetail":"Fluphenazine Enanthate is a potent antagonist of the D3 dopamine receptor, which is involved in the regulation of motor function and cognition. By blocking this receptor, it reduces the abnormal activity of dopamine in the brain, leading to a decrease in psychotic symptoms."},"commercial":{"launchDate":"1967","_launchSource":"DrugCentral (FDA 1967-03-15, APOTHECON)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1214","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUPHENAZINE ENANTHATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:36:11.035328","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:04.552834+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"brexpiprazole","drugSlug":"brexpiprazole","fdaApproval":"2015-07-10","patentExpiry":"Oct 12, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bromocriptine","drugSlug":"bromocriptine","fdaApproval":"1978-06-28","patentExpiry":"Jun 7, 2030","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"fluphenazine enanthate","indications":{"approved":[{"name":"Psychotic disorder","source":"DrugCentral","snomedId":69322001,"regulator":"FDA"},{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"brexpiprazole","brandName":"brexpiprazole","genericName":"brexpiprazole","approvalYear":"2015","relationship":"same-target"},{"drugId":"bromocriptine","brandName":"bromocriptine","genericName":"bromocriptine","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179195","MMSL":"3882","NDDF":"001473","UNII":"QSB34YF0W9","VUID":"4017724","CHEBI":"CHEBI:5125","VANDF":"4017724","INN_ID":"946","RXNORM":"30129","UMLSCUI":"C0066682","chemblId":"CHEMBL1200951","ChEMBL_ID":"CHEMBL1200951","KEGG_DRUG":"D00792","DRUGBANK_ID":"DB00623","PUBCHEM_CID":"3389","SNOMEDCT_US":"111125005","MESH_DESCRIPTOR_UI":"D005476","MESH_SUPPLEMENTAL_RECORD_UI":"C017610"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1967-","companyName":"Apothecon","relationship":"Original Developer"}],"publicationCount":126,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"originalDeveloper":"Apothecon","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"1967","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1967-03-15T00:00:00.000Z","mah":"APOTHECON","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:04.552834+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}